Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TACR1 | P25103 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1000168 | 0.99 | L3MBTL1 (0.53) | L3MBTL1ATMALDH1A1TACR1MEN1 | |
| SCHEMBL1622710 | 0.89 | ALDH1A1 (0.57) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| SCHEMBL31351576 | 0.89 | KDM4E (0.66) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| SCHEMBL4948411 | 0.88 | MEN1 (0.54) | L3MBTL1ATMALDH1A1TACR1MEN1 | |
| Hydrochloric Acid SCHEMBL1621693 | 0.88 | ALDH1A1 (0.56) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| SCHEMBL183706 | 0.87 | ALDH1A1 (0.52) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| SCHEMBL1339973 | 0.87 | TACR1 (0.53) | TACR1SIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL30994721 | 0.87 | TACR1 (0.53) | TACR1SIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL27560073 | 0.87 | TACR1 (0.48) | L3MBTL1ATMALDH1A1TACR1MEN1 | |
| Hydrochloric Acid SCHEMBL719130 | 0.86 | TACR1 (0.54) | TACR1SIGMAR1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353863-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | INST NAT SANTE RECH MED (FR) | 2025-11-20 | — | — | US | disclosed |
| EP-4536667-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-04-16 | — | — | EP | disclosed |
| CN-115348959-B | Heteroaryl compounds and their therapeutic use in conditions associated with altered beta-glucocerebrosidase activity | GT增益治疗股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-117229280-A | Method for preparing capromorelin | 洛阳惠中兽药有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023237580-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023237580-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2023-12-14 | — | — | WO | disclosed |
| CN-114456286-B | Catalyst system for olefin polymerization and application thereof | 中国石油化工股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-3419972-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-07-26 | — | — | EP | disclosed |
| CN-114456290-B | Catalyst system for olefin polymerization and prepolymerized catalyst composition | 中国石油化工股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230107499-A1 | HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2023-04-06 | — | — | US | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| US-6258825-B1 | ANALGESIC, A RELIEVER AGAINST TOLERANCE TO A NARCOTIC ANALGESIC REPRESENTED BY MORPHINE, REMEDY FOR PARKINSONISM, A REMEDY FOR CHOREA, AN ANTIDEPRESSANT, A REMEDY FOR DIABETES INSIPIDUS, A REMEDY FOR POLYURIA, OR HYPOTENSION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-07-10 | — | — | US | disclosed |
| CN-1258294-A | 2-oxoimidazole derivs. | BANYU PHARMA CO LTD (JP) | 2000-06-28 | — | — | CN | disclosed |
| EP-0990653-A1 | 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-5821240-A | ENZYME INHIBITORS, SIGNAL INHIBITORS FOR ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS AND HORMONE INHIBITORS | DR. KARL THOMAE GMBH (DE) | 1998-10-13 | — | — | US | disclosed |
| US-3962448-A | CNS DEPRESSANTS, VETERINARY | SMITHKLINE CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | L3MBTL1 690/4885ATM 2455/4885ALDH1A1 3599/4885 |
| US-20230107499-A1 | HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | GBA1, GBA2, GBA3 | L3MBTL1 219/4885ATM 3636/4885ALDH1A1 640/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | L3MBTL1 876/4885ATM 2241/4885ALDH1A1 3941/4885 |
| US-20250353863-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | TALDO1, TBCA, TBCD | L3MBTL1 971/4885ATM 1175/4885ALDH1A1 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.